

**SUPPLEMENTARY TABLE. Trends in vaccination coverage for selected vaccines and doses by age 24 months\* among children eligible† for the Vaccines for Children program and difference in coverage between program-eligible and non-program-eligible children born during 2011–2020 — National Immunization Survey to Child, United States, 2012–2022**

Vaccine Measure		Birth Year										AAPPC <sup>‡</sup>
		2011	2012	2013	2014	2015	2016	2017	2018	2019	2020 <sup>§</sup>	
DTaP** (≥4 doses)	Coverage % (95% CI)	76.0 (73.8 to 78.2)	77.2 (75.2 to 79.2)	77.7 (75.8 to 79.6)	76.0 (73.7 to 78.2)	77.0 (74.9 to 79.0)	74.8 (72.4 to 77.3)	76.2 (74.3 to 78.1)	77.1 (75.2 to 78.9)	76.6 (74.6 to 78.6)	75.9 (73.1 to 78.7)	-0.1 (-0.3 to 0.2)
	PP diff. (95% CI)	-10.0 (-12.7 to -7.3)**	-9.2 (-11.7 to -6.7)**	-7.6 (-10.1 to -5.1)**	-8.7 (-11.7 to -5.7)**	-8.8 (-11.3 to -6.2)**	-11.1 (-14.0 to -8.2)**	-9.6 (-12.0 to -7.1)**	-10.7 (-12.9 to -8.6)**	-9.5 (-11.9 to -7.1)**	-10.1 (-13.5 to -6.7)**	-0.2 (-0.4 to 0.1)
Poliovirus (≥3 doses)	Coverage % (95% CI)	89.7 (87.8 to 91.3)	91.8 (90.6 to 92.9)	91.1 (89.8 to 92.3)	89.1 (87.2 to 90.9)	90.4 (88.9 to 91.7)	89.7 (88.0 to 91.3)	89.0 (87.5 to 90.4)	92.0 (90.8 to 93.0)	90.5 (89.1 to 91.7)	91.4 (89.6 to 92.9)	0.0 (-0.3 to 0.3)
	PP diff. (95% CI)	-5.0 (-7.0 to -2.9)**	-2.7 (-4.1 to -1.3)**	-2.7 (-4.3 to -1.1)**	-4.0 (-6.4 to -1.6)**	-4.5 (-6.1 to -2.9)**	-5.7 (-7.5 to -3.9)**	-5.1 (-6.9 to -3.4)**	-3.7 (-5.0 to -2.3)**	-5.2 (-6.7 to -3.7)**	-3.3 (-5.3 to -1.3)**	-0.1 (-0.4 to 0.1)
Hib – Full Series <sup>§§</sup>	Coverage % (95% CI)	75.4 (73.2 to 77.5)	76.5 (74.6 to 78.5)	78.1 (76.2 to 79.9)	75.2 (72.8 to 77.4)	75.8 (73.7 to 77.9)	75.5 (73.2 to 77.9)	74.0 (71.9 to 76.1)	74.6 (72.7 to 76.5)	76.1 (74.1 to 78.0)	73.6 (70.8 to 76.4)	-0.2 (-0.5 to 0.1)
	PP diff. (95% CI)	-9.7 (-12.5 to -7.0)**	-7.9 (-10.6 to -5.2)**	-6.0 (-8.4 to -3.6)**	-9.3 (-12.3 to -6.4)**	-8.8 (-11.4 to -6.1)**	-9.0 (-11.9 to -6.2)**	-10.6 (-13.2 to -7.9)**	-11.3 (-13.7 to -9.0)**	-8.0 (-10.4 to -5.6)**	-9.6 (-12.9 to -6.2)**	-0.2 (-0.6 to 0.2)
HepB (Birth dose) <sup>¶¶</sup>	Coverage % (95% CI)	75.9 (73.7 to 78.0)	75.0 (72.8 to 77.0)	75.7 (73.6 to 77.7)	72.7 (70.0 to 75.3)	74.8 (72.0 to 77.3)	75.3 (72.7 to 77.6)	77.7 (75.7 to 79.6)	78.4 (76.4 to 80.2)	81.6 (79.8 to 83.2)	80.7 (78.2 to 82.9)	0.7 (0.3 to 1.2)***
	PP diff. (95% CI)	5.8 (2.8 to 8.8)**	4.8 (1.9 to 7.7)**	6.6 (3.8 to 9.4)**	4.4 (0.8 to 8.0)**	2.8 (-0.6 to 6.3)	-0.6 (-3.7 to 2.4)	1.0 (-1.6 to 3.6)	-1.4 (-3.9 to 1.0)	0.1 (-2.2 to 2.3)	-1.6 (-4.6 to 1.4)	-0.9 (-1.3 to -0.6)***
HepB (≥3 doses)	Coverage % (95% CI)	88.9 (87.2 to 90.4)	91.3 (90.0 to 92.4)	91.1 (89.8 to 92.3)	88.9 (87.0 to 90.6)	89.5 (87.9 to 90.9)	89.5 (87.7 to 91.2)	89.8 (88.3 to 91.2)	91.2 (89.9 to 92.4)	91.0 (89.8 to 92.2)	90.7 (88.9 to 92.3)	0.1 (-0.2 to 0.3)
	PP diff. (95% CI)	-2.0 (-4.1 to 0.1)	-0.4 (-2.0 to 1.2)	-1.1 (-2.7 to 0.6)	-2.5 (-4.9 to -0.1)**	-2.4 (-4.5 to -0.2)**	-3.8 (-5.7 to -1.8)**	-2.7 (-4.5 to -0.9)**	-2.7 (-4.3 to -1.2)**	-3.2 (-4.7 to -1.8)**	-1.8 (-3.9 to 0.4)	-0.2 (-0.4 to 0.0)***
Varicella (≥1 dose)	Coverage % (95% CI)	87.8 (86.0 to 89.4)	89.0 (87.6 to 90.2)	88.4 (86.9 to 89.8)	86.5 (84.5 to 88.4)	88.2 (86.6 to 89.7)	88.7 (87.1 to 90.2)	88.0 (86.4 to 89.4)	88.9 (87.4 to 90.3)	88.3 (86.8 to 89.8)	89.8 (87.9 to 91.4)	0.1 (-0.1 to 0.3)
	PP diff. (95% CI)	-3.2 (-5.3 to -1.0)**	-2.6 (-4.3 to -1.0)**	-2.5 (-4.5 to -0.5)**	-5.3 (-7.7 to -2.8)**	-4.3 (-6.2 to -2.5)**	-3.2 (-5.2 to -1.3)**	-4.0 (-5.9 to -2.0)**	-4.7 (-6.4 to -3.0)**	-5.7 (-7.4 to -3.9)**	-3.0 (-5.2 to -0.8)**	-0.2 (-0.5 to 0.0)
PCV (≥4 doses)	Coverage % (95% CI)	75.7 (73.4 to 77.8)	78.5 (76.6 to 80.3)	78.1 (76.2 to 80.0)	76.7 (74.5 to 78.9)	76.5 (74.3 to 78.6)	76.2 (73.8 to 78.6)	75.5 (73.4 to 77.5)	78.2 (76.4 to 79.9)	78.3 (76.4 to 80.1)	76.7 (73.9 to 79.4)	0.0 (-0.3 to 0.4)
	PP diff. (95% CI)	-11.1 (-13.8 to -8.3)**	-8.6 (-11.1 to -6.1)**	-7.7 (-10.2 to -5.3)**	-9.2 (-12.1 to -6.2)**	-9.5 (-12.2 to -6.7)**	-10.5 (-13.3 to -7.6)**	-11.0 (-13.6 to -8.5)**	-11.1 (-13.2 to -9.0)**	-10.3 (-12.6 to -8.1)**	-11.3 (-14.6 to -8.1)**	-0.2 (-0.5 to 0.0)
HepA (≥1 dose)	Coverage % (95% CI)	80.0 (77.9 to 82.0)	82.0 (80.2 to 83.7)	82.1 (80.3 to 83.8)	81.6 (79.5 to 83.6)	82.8 (81.0 to 84.5)	83.0 (81.0 to 85.0)	84.2 (82.5 to 85.7)	85.6 (84.0 to 87.1)	85.6 (83.9 to 87.1)	86.9 (84.9 to 88.8)	0.7 (0.5 to 0.8)***
	PP diff. (95% CI)	-1.3 (-3.9 to 1.3)	-1.9 (-4.4 to 0.6)	-2.2 (-4.5 to 0.2)	-4.1 (-6.9 to -1.4)**	-4.1 (-6.4 to -1.7)**	-4.6 (-7.1 to -2.2)**	-3.6 (-5.8 to -1.5)**	-4.8 (-6.7 to -2.8)**	-5.6 (-7.5 to -3.7)**	-3.3 (-5.8 to -0.9)**	-0.4 (-0.6 to -0.1)***
Influenza (≥2 doses) <sup>***</sup>	Coverage % (95% CI)	45.8 (43.3 to 48.3)	46.8 (44.4 to 49.2)	46.2 (43.9 to 48.7)	43.5 (40.9 to 46.2)	48.1 (45.5 to 50.9)	47.2 (44.6 to 49.8)	48.2 (45.9 to 50.5)	51.6 (49.4 to 53.8)	52.4 (50.2 to 54.7)	46.2 (43.3 to 49.3)	0.6 (0.0 to 1.2)***
	PP diff. (95% CI)	-14.7 (-18.0 to -11.4)**	-16.0 (-19.2 to -12.8)**	-16.1 (-19.3 to -13.0)**	-19.5 (-23.1 to -15.9)**	-16.8 (-20.3 to -13.3)**	-19.2 (-22.5 to -15.9)**	-20.6 (-23.5 to -17.6)**	-23.4 (-26.1 to -20.7)**	-23.4 (-26.2 to -20.7)**	-26.2 (-29.9 to -22.5)**	-1.2 (-1.5 to -0.9)***

**Abbreviations:** AAPPC = average annual percentage point change in coverage; AI/AN = American Indian or Alaska Native; diff = difference; DTaP = diphtheria and tetanus toxoids and acellular pertussis vaccine; HepA = hepatitis A vaccine; HepB = hepatitis B vaccine; Hib = *Haemophilus influenzae* type b conjugate vaccine; PCV = pneumococcal conjugate vaccine; PP = percentage point; VFC = Vaccines for Children.

\*Includes vaccinations received by age 24 months (before the day the child turns 24 months), except for the HepB birth dose. For all vaccines other than the HepB birth dose, the Kaplan-Meier method was used to estimate vaccination coverage to account for children whose vaccination history was ascertained before age 24 months. The HepB birth dose was measured as the proportion of children who received a dose of HepB by age 3 days.

†Child is AI/AN; insured by Medicaid or Indian Health Service; uninsured; or received any vaccines at an Indian Health Service to operated center, Tribal health facility, or urban Indian health care facility.

§Data for the 2020 birth year are considered preliminary and are from survey years 2021 and 2022 (data from survey year 2023 are not yet available).

<sup>¶</sup>Slope of line created by fitting a linear regression model to the coverage estimates from birth years 2011–2020.

\*\*Includes children who may have been vaccinated with diphtheria and tetanus toxoids vaccine or diphtheria and tetanus toxoids and pertussis vaccine.

<sup>††</sup>Statistically significant ( $p < 0.05$ ) percentage point difference in coverage (VFC-eligible – non-VFC-eligible).

<sup>§§</sup>Hib Full Series: primary series and booster dose, which includes receipt of  $\geq 3$  or  $\geq 4$  doses, depending on product type received.

<sup>¶¶</sup>One dose HepB administered from birth through age 3 days.

\*\*\*AAPP is statistically significantly different from zero ( $p < 0.05$ ).

<sup>†††</sup>Doses must be at least 24 days apart (4 weeks with a 4 day grace period); doses could have been received during two influenza seasons.